Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Because of the recent approval by the FDA, it is anticipated payers will see an up-tick in the number of requests for this new drug. Because Journavx is not listed on the formulary, all requests ...

RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

It’s called Journavx, made by Vertex Pharmaceuticals ... an additional tool in the future for use in chronic pain conditions. Right now, it’s only FDA approved for acute pain. This drug was studied ...

On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain. For the healthcare industry, this can be a valuable ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...